ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 0.00 shares.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 2.87K shares, a 99.07% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 308.73K shares, a 0.19% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 309.30K shares, a 2581.67% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 11.53K shares, a 80.20% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-05 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-06 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-25 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-25 | 2.87K shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 0.00 shares derived: sum of 2 quarters · filed 2025-10-28 | 2.87K shares 10-Q · filed 2025-10-28 | 2.87K shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.87K shares 10-Q · filed 2025-08-06 | 2.87K shares derived: sum of 3 quarters · filed 2025-08-06 | 3.15K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 2.87K shares 10-Q · filed 2025-05-06 | 2.87K shares derived: sum of 2 quarters · filed 2025-05-06 | 3.15K shares derived: sum of 3 quarters · filed 2025-05-06 | 140.16K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 281.00 shares derived: sum of 2 quarters · filed 2025-02-25 | 137.30K shares derived: sum of 3 quarters · filed 2025-02-25 | 308.73K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 281.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 137.30K shares derived: sum of 2 quarters · filed 2024-11-06 | 308.73K shares 10-Q · filed 2024-11-06 | 480.77K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 137.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 308.44K shares 10-Q · filed 2024-08-14 | 480.49K shares derived: sum of 3 quarters · filed 2024-08-14 | 541.38K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 171.43K shares 10-Q · filed 2024-05-14 | 343.47K shares derived: sum of 2 quarters · filed 2024-05-14 | 404.37K shares derived: sum of 3 quarters · filed 2024-05-14 | 465.42K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 172.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 232.94K shares derived: sum of 2 quarters · filed 2024-02-27 | 294.00K shares derived: sum of 3 quarters · filed 2024-02-27 | 309.30K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 60.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 121.95K shares derived: sum of 2 quarters · filed 2023-11-03 | 137.26K shares 10-Q · filed 2023-11-03 | 144.38K shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 61.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 76.37K shares 10-Q · filed 2023-08-08 | 83.49K shares derived: sum of 3 quarters · filed 2023-08-08 | 83.71K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 15.31K shares 10-Q · filed 2023-05-09 | 22.43K shares derived: sum of 2 quarters · filed 2023-05-09 | 22.65K shares derived: sum of 3 quarters · filed 2023-05-09 | 22.65K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 7.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 7.34K shares derived: sum of 2 quarters · filed 2023-02-28 | 7.34K shares derived: sum of 3 quarters · filed 2023-02-28 | 11.53K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 219.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 219.00 shares derived: sum of 2 quarters · filed 2022-11-08 | 4.41K shares 10-Q · filed 2022-11-08 | 34.99K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 4.19K shares 10-Q · filed 2022-08-04 | 34.77K shares derived: sum of 3 quarters · filed 2022-08-04 | |
| 2022-03-31 | 4.19K shares 10-Q · filed 2022-05-05 | 34.77K shares derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2021-12-31 | 30.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | 58.24K shares 10-K · filed 2022-02-22 | ||
| 2021-09-30 | 27.66K shares 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | 13.12K shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |